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SUMMARY
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The World Health Organization (WHO) has set a target
of treating 3 million people with antiretroviral treatment
(ART) by 2005. In sub-Saharan Africa, HIV-positive
tuberculosis (TB) patients could signiﬁcantly contribute
to this target. ART (stavudine/lamivudine/nevirapine)
was initiated in Thyolo district, Malawi, in April 2003,
and all HIV-positive TB patients were considered eli-
gible and offered ART. Despite this, only 44 (13%) of
352 TB patients were eventually started on ART by the end
of November 2003. Most TB patients leave hospital after 2
weeks to complete the initial phase of anti-tuberculosis
treatment (rifampicin-based) in the community, and
ART is offered to HIV-positive TB patients after they
have started the continuation phase of treatment (isoniazid/
ethambutol). ART is only offered at hospital, while the
majority of TB patients take their continuation phase
of anti-tuberculosis treatment from health centres.
HIV-positive TB patients therefore ﬁnd it difﬁcult to
access ART.
In this paper, we discuss a series of options to increase
the uptake of ART among HIV-positive TB patients.
The main options are: 1) to hospitalise HIV-positive TB
patients with a view to starting ART in the continuation
phase in hospital; 2) to decentralise ART delivery so
ART can be delivered at health centres; 3) to replace
nevirapine with efavirenz so ART can be started earlier
in the initial phase of anti-tuberculosis treatment. De-
centralisation of ART from hospitals to health centres
would greatly improve ART access.
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IN SETTINGS of high human immunodeﬁciency
virus (HIV) prevalence, tuberculosis (TB) and HIV
programmes have mutual interest in collaborating
with each other. HIV infection is fuelling the TB epi-
demic, and TB continues to be the most common cause
of morbidity and mortality in HIV-positive popula-
tions.1,2 TB is often what brings the HIV-positive in-
dividual to medical attention, and individuals pre-
senting with TB in high HIV prevalence settings are
likely to be co-infected with HIV. The World Health
Organization (WHO) has set an ambitious target of
treating 3 million people with antiretroviral treatment
(ART) by 2005, the so-called ‘3 by 5’ target.3 As TB
patients constitute a readily identiﬁable group in the
health system for HIV testing and ART, they could
signiﬁcantly contribute to this target.
Malawi, a small, resource-poor country in central
southern Africa, has an estimated national HIV prev-
alence rate of 9%, with 900000 people thought to be
HIV-infected.4 In 2000, a countrywide survey found
that 77% of new patients registered with TB were co-
infected with HIV.5 Thyolo district, in rural southern
Malawi, has been pioneering joint TB-HIV interven-
tions and ART for HIV-positive eligible patients, in-
cluding TB patients, in the country. According to the
Malawi ART guidelines6 and WHO guidelines,3 all
HIV-positive individuals in WHO Stage III or IV are el-
igible for ART. HIV-positive individuals with pulmo-
nary TB (PTB) are classiﬁed as WHO Stage III and
those with extra-pulmonary TB (EPTB) are classiﬁed
as WHO Stage IV.
ART (stavudine/lamivudine/nevirapine) was initi-
ated in the main public hospital in Thyolo district
(Thyolo District Hospital) on 22 April 2003; by the
end of November 2003, 345 HIV-positive individuals
had been placed on treatment. Because the initial phase
of anti-tuberculosis treatment for new TB patients is
rifampicin (R, RMP) based and because of drug inter-
actions between RMP and nevirapine,3 ART is cur-
rently offered to all HIV-positive TB patients only after
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completing the initial 2 months of anti-tuberculosis
treatment (Table 1). During this same period, 352 HIV-
positive TB patients had completed this initial phase
of anti-tuberculosis treatment and went on to start the
continuation phase, consisting of isoniazid (H, INH)
and ethambutol (E, EMB). Although all these TB pa-
tients were eligible for ART and were informed of the
offer, only 44 (13%) were eventually started on ART
(Figure 1). This relatively low uptake of ART in HIV-
positive TB patients is of concern. The problem is
likely to lie within the TB-HIV patient circuit and
result from the fact that anti-tuberculosis treatment
is largely decentralised,7 while HAART is centralised
and currently available at only one site (Thyolo Dis-
trict Hospital). Is it possible to get more HIV-positive
patients with active TB on ART? In this paper, we de-
scribe the circuit of a TB patient in terms of TB man-
agement and ART in Thyolo District Hospital. We
then discuss possible options to try and increase the
current uptake of ART in HIV-positive individuals
with active TB.
MANAGEMENT OF TB AND ART IN 
HIV-POSITIVE TB PATIENTS
Circuit of TB patients in Thyolo
The circuit of TB patients in terms of TB management
and ART in Thyolo District Hospital, Malawi, is shown
in Figure 2.
Management of TB
All patients diagnosed with TB are registered and
started on standardised anti-tuberculosis treatment
according to national guidelines.8 Table 1 shows the
different TB treatment regimens and their indications.
In the RMP-based initial phase of treatment, patients
are admitted to the hospital TB wards for 2 weeks,
during which they receive directly observed anti-
tuberculosis treatment. During these 2 weeks they
also receive information, education and communica-
tion (IEC) sessions on TB and HIV/acquired immune-
deﬁciency syndrome (AIDS). They are then allowed
to go home if ﬁt enough, and receive the remaining 6
weeks of intermittent initial phase treatment under
supervision of a health centre, a guardian (guardian-
based treatment) or the hospital if the patient lives
close by and agrees to continue treatment on an am-
bulatory basis. Drugs are administered three times a
week, on Monday, Wednesday and Friday, over the
6-week period. Once patients have completed the initial
Table 1 Tuberculosis (TB) treatment regimens
Type of TB
Drug regimens and 
duration* Comments
New smear-positive PTB and serious EPTB 0.5RHZE/1.5R3H3Z3E3/6EH Initial phase: Initial 2 weeks daily RHZE in hospital; 6 weeks 
intermittent RHZE in hospital, under health centre 
supervision or guardian supervision. 
Continuation phase: 6 months daily EH
New smear-negative PTB and less serious EPTB 0.5RHZ/1.5R3H3Z3/6EH Initial phase: Initial 2 weeks daily RHZ in hospital; 6 weeks 
intermittent RHZ in hospital, under health centre 
supervision or guardian supervision. 
Continuation phase: 6 months daily EH
Retreatment of smear-positive PTB relapses, 
failure cases and cases who return after 
default
2SRHZE/1RHZE/5R3H3Z3E3  Initial phase: 2 months daily SRHZE in hospital; 1 month 
daily RHZE, usually in hospital. 
Continuation phase: 5 months intermittent treatment in 
hospital, health centre or guardian supervision.
TB meningitis in adults and children 2SRHZ/7RH  Initial phase: 2 months daily SRHZ in hospital. 
Continuation phase: 7 months daily RH in hospital, health 
centre or guardian supervision.
*A regimen consists of two phases—initial phase and continuation phase. The number before a phase is the duration of that phase in months. A number in
subscript after a letter is the number of doses of that drug per week. If there is no number in subscript after a letter, then treatment is daily.
PTB 5 pulmonary tuberculosis; EPTB 5 extra-pulmonary tuberculosis; R 5 rifampicin; H 5 isoniazid; Z 5 pyrazinamide; E 5 ethambutol; S 5 streptomycin.
Figure 1 Uptake of ART among HIV-positive tuberculosis (TB)
patients in Thyolo, Malawi. *Individuals who had completed
their initial phase (2 months) of anti-tuberculosis treatment and
were supposed to start ART during the period April to Novem-
ber 2003. VCT 5 voluntary counselling and HIV testing; HIV 5
human immunodeﬁciency virus; ART 5 antiretroviral treatment.240 The International Journal of Tuberculosis and Lung Disease
phase, they are put on the 6-month continuation
phase (HE), when they are given drugs on a monthly
basis. All drugs and investigations for TB are free of
charge.
VCT and HIV care-related activities
Since early 1999, all registered TB patients have been
systematically offered access to HIV voluntary coun-
selling and testing (VCT). Individuals undergo pre-
test counselling on a one-to-one basis. HIV testing is
done on site using rapid whole blood testing kits.
Those who accept HIV testing are offered post-test
counselling. HIV-positive individuals are offered co-
trimoxazole (CTX) prophylaxis provided there are
no contraindications.9 CTX is taken during the entire
course of anti-tuberculosis treatment, and indeﬁnitely
thereafter. The uptake of VCT and CTX in this set-
ting has been over 90%,9 and adherence to CTX
during and after anti-tuberculosis treatment has been
excellent.10,11 All HIV-positive TB patients are also
screened and treated for HIV-related opportunistic
infections while on the ward, and all TB patients receive
nutritional support while hospitalised. There are links
with community care groups and home-based care
volunteers who provide continuing support and en-
hance adherence through counselling.
ART regimens
The ﬁrst-line ART regimen in Malawi consists of sta-
vudine (d4T), lamivudine (3TC) and nevirapine (NVP),
available as a ﬁxed-dose combination (FDC). The
basic reasons for choosing this combination as a ﬁrst-
line regimen included the need for standardised ther-
apy across the country, ease of administration (one
Figure 2 Circuit of a TB patient for receiving TB management and ART in Thyolo District Hospi-
tal, Malawi. *Supervised drug administration 3 times a week. VCT 5 voluntary counselling and
HIV testing; OI 5 opportunistic infections; ART 5 antiretroviral treatment; D4T 5 stavudine, 3TC 5
lamuvudine, NVP 5 niverapine; Triomune® 5 ﬁxed-dose combination of d4T/3TC/NVP.Getting more TB patients on antiretroviral treatment 241
pill twice daily), few short-term side effects, no need
for mandatory laboratory monitoring,3,6 positive pre-
vious experiences and relatively low cost. Two three-
drug FDCs of d4T, 3TC and NVP are currently avail-
able: d4T40/3TC/NVP (Triomune® or Triviro LNS®-
40) for patients weighing >60 kg and d4T30/3TC/
NVP (Triomune® or Triviro LNS®-30) for those
weighing  ,60 kg. A two-drug FDC of d4T and 3TC
is also currently available: d4T40/3TC (Coviro LS®-
40) and d4T30/TC (Coviro LS®-30) for individuals
weighing > or ,60 kg, respectively.
Zidovudine (AZT) can be used as an alternative to
d4T in case of severe d4T-associated peripheral neu-
ropathy. Efavirenz (EFV) replaces NVP in case of
NVP-associated hepatitis, liver disease, severe skin re-
actions or if a patient is taking RMP-containing anti-
tuberculosis treatment. The second-line regimen in case
of failure of the ﬁrst-line regimen is a combination of
AZT, didanosine (ddI) and nelﬁnavir (NFV). This may
be reviewed in the light of the recently released 2003
version of the WHO ART guidelines.12
ART eligibility for HIV-positive TB patients
In Malawi, individuals with TB are potentially eligible
for ART because they are categorised as WHO Clini-
cal Stage III or IV.3,6 ART is not given during the ini-
tial phase of anti-tuberculosis treatment because of the
interaction between RMP and NVP (all drug combi-
nations in the initial phase of anti-tuberculosis treat-
ment include RMP) (Table 1). Once the patient has
completed the initial phase of treatment and has started
on the continuation phase, consisting of INH and
EMB, the patient is eligible to start ART. Because RMP
has a long half-life, ART with D4T/3TC/NVP is only
started after the patient has been on EH for 1–2 weeks.
Steps for providing ART for HIV-positive TB patients 
(Figure 2)
• HIV-positive TB patients are seen in the hospital HIV-
ART clinic 8 weeks after starting anti-tuberculosis
treatment in conjunction with a patient guardian.
Due attention is paid to conﬁdentiality and informed
consent.
• The individual undergoes medical screening by the
clinical ofﬁcer and participates with the guardian
in a group counselling session about antiretroviral
(ARV) drugs, the importance of strict adherence to
therapy and what to do in case of side effects.
• In Thyolo, blood is then taken for CD4-lympho-
cyte count, total lymphocyte count, haemoglobin
and liver function testing (alanine aminotrans-
ferase, ALT) to monitor the current clinical admis-
sion and monitoring protocol. According to the
current Malawi ART protocol, however, these tests
are not mandatory.6
• One week later, when the laboratory results are
available, the patient undergoes individual coun-
selling on a one-to-one basis.
• The patient is weighed and prescribed Triomune®-
30 or Triomune®-40, depending on body weight. In
case of speciﬁc contraindications to NVP or D4T,
respectively EFV or AZT could be considered as
alternatives.
• Patients are given one tablet of Triomune® in the
morning and one tablet of combined d4T/3TC
(Coviro LS®) at night for 14 days. Treatment is
introduced in this manner, with a lead in the NVP
dose, due to the need to reduce the risk of NVP-
induced rash.
• TB patients also receive EH, and pyridoxine 10 mg
daily. If TB patients are taking CTX prophylaxis,
this is also continued along with ART.
• Patients are reviewed at the HIV-ART clinic after
the initial 2 weeks of ARV drugs.
• From then on, provided there are no side effects,
patients are seen and given their drugs every 14
days, then every 28 days (4 weeks) until the end of
anti-tuberculosis treatment. Once anti-tuberculosis
treatment has been completed patients receive their
drugs every 56 days (8 weeks). They are now advised
to take one tablet of Triomune® in the morning and
one in the evening. Thus, getting a patient onto a
simple daily regimen of one pill of Triomune twice
daily requires three visits to the hospital over a
period of 3 weeks (Figure 2).
• If any side effects are experienced between clinic
visits, patients are educated about the need to
report to a health facility.
• Patients on the retreatment regimen containing RMP
throughout are immediately considered for the
alternative ﬁrst-line ART regimen; e.g., d4T/3TC/
EVF. Women placed on EFV are given appropriate
contraceptive advice.
• ART and laboratory tests are provided free of charge
in Thyolo.
OPTIONS FOR INCREASING THE UPTAKE OF 
ART IN HIV-POSITIVE TB PATIENTS
The possible options for trying to increase the current
uptake of ART in HIV-positive individuals with ac-
tive TB are not exclusive of one another and take into
account the current ﬁrst-line ART regimen as well as
the patient circuit in Thyolo.
Option: Hospitalise HIV-positive TB patients for an 
initial period of 12 weeks
Rationale and advantages
In the current setting, TB treatment is centralised for
an initial period of 2 weeks, after which it is decen-
tralised. The ART programme, however, remains cen-
tralised at the hospital. HIV-positive TB patients start-
ing ART will be expected to return to hospital several
times, ﬁrst for ART initiation and then for follow-up.
In our setting, 25% of all newly registered TB patients
are moribund on admission;9 57% are malnourished,242 The International Journal of Tuberculosis and Lung Disease
and 35% have moderate to severe malnutrition.13 The
majority of patients are destitute due to their chronic
illness and the loss of work capacity. Expecting ill and
destitute TB patients to travel to one site to receive
their anti-tuberculosis treatment and then again to
travel on multiple occasions to hospital for ART is
likely to be unrealistic and unfeasible for most pa-
tients, particularly those living in remote areas.14 Of-
fering the option of remaining in hospital during the
ﬁrst 12 weeks of anti-tuberculosis treatment, when
most ART-related visits are required, could introduce
a number of potential advantages for the patient.
First, patients who are particularly ill or unable to
make multiple journeys for any reason will be able to
complete their initial phase of anti-tuberculosis treat-
ment and initiate ART while in hospital. This would
reduce the overall burden of travel. Second, the ﬁrst 2
weeks of ART would be initiated on the ward, allow-
ing the patient to be monitored closely. The longer pe-
riod of hospitalisation is likely to have the additional
advantage that HIV-related opportunistic infections
are well taken care of and the nutritional status of
most patients improves. Requesting patients to return
to hospital once a month thereafter is less demanding
and likely to be more feasible. Third, patients would
have the added advantage of having access to hospital-
based counsellors to clarify any additional concerns
following the initial counselling sessions.
Operational considerations
The introduction of such a strategy has the following
implications:
First, there will be a need to assess who might be
willing to stay in hospital for 3 months from the start.
This assessment could be undertaken during the ini-
tial counselling process.
Second, Malawi has progressively achieved decen-
tralisation of anti-tuberculosis treatment.7 This strat-
egy has resulted in an improved turnover of patients
in the TB wards, a large reduction in overall bed oc-
cupancy rates, and has probably brought economic
savings to the health system.15 Hospitalising HIV-
positive TB patients, who comprise close to 77% of
all newly registered TB patients5 in our setting, would
unavoidably reverse some of these gains, and TB
wards run the risk of becoming over-congested again.
In Malawi, total available bed space for all types of
TB is generally limited, and individuals with smear-
negative PTB or EPTB are often admitted to the gen-
eral wards along with admissions for other medical
conditions. As the HIV prevalence rate in smear-
negative PTB and EPTB patients is close to 80%,5 the
option of hospitalising such patients for 3 months
would undoubtedly reduce overall bed availability
for patients with conditions other than TB. Further-
more, although patients with smear-negative PTB and
EPTB are less infectious than those with smear-positive
TB, there is still a risk of TB transmission.16 In our
setting, 50% or more of all non-TB patients admitted
to medical wards are HIV-positive.17 There is there-
fore a potential risk of nosocomial TB transmission to
this group of susceptible individuals, if they spend
longer periods of time with larger numbers of TB pa-
tients in already overcrowded conditions.
Third, for a patient to spend 3 months in a hospi-
tal, often far from home, is likely to have implications
for the household in terms of transport logistics and
time spent off work by family members visiting hos-
pital. Patients with TB also tend to feel better after 2
weeks of anti-tuberculosis treatment and, in such cir-
cumstances, prefer to continue treatment in the com-
munity.7 In Thyolo, which has a network of home-based
care volunteers, peer groups and nurses providing
continuing support and care within the community,
this is another reason why patients might be inclined
to return to their homes.
Fourth, an estimated 50% of Ministry of Health
(MoH) posts remain unﬁlled,18 and the increase in
daily workload due to more TB patients on the wards
is an important concern.
It is therefore unlikely that Malawi’s National TB
Programme (NTP) will want to hospitalise TB pa-
tients for 12 weeks, having already embarked on a
policy of decentralisation.
Option: Decentralise ART to health centres after 
hospital-based initiation of ART
Rationale and advantages
If HIV-positive TB patients have been started on ART
in the hospital setting, the option of decentralising the
continuation of ART to health centres along with
the continuation phase of anti-tuberculosis treatment
would have a number of advantages.
First, the need to visit a health centre to collect the
monthly supply of anti-tuberculosis drugs and then
the hospital for the ART drugs could be avoided. The
patient could collect the drugs for both the continuation
phase of anti-tuberculosis treatment as well as ART
at the health centre.
Second, the workload on a centralised hospital-
based ART clinic would be progressively reduced as
patient follow-up becomes decentralised to health
centre level. This is an important consideration for
scaling up ART. Some trained medical assistants and
nurses working at health centres in Thyolo are al-
ready satisfactorily managing HIV-related opportu-
nistic infections. Follow-up of patients who are stable
and simply require regular supplies of ART should
also be feasible in such centres.
Third, overall adherence to ART in the long term is
likely to be enhanced, as individuals will have access
to both TB and ARV treatment at a site closer to their
residence. We have very encouraging evidence of ad-
herence to CTX prophylaxis during and after anti-
tuberculosis treatment in Thyolo.10,11 Unlike theGetting more TB patients on antiretroviral treatment 243
current situation with ART, CTX prophylaxis is de-
centralised with anti-tuberculosis treatment, and is
made available in all health centres. Patients thus re-
ceive their monthly supply of CTX along with their
anti-tuberculosis drugs. We also know that patients
are committed to taking their drugs and that those
who stop treatment do so mainly because of transport
problems associated with long distance travel.11
Operational considerations
Decentralising ARV drugs along with anti-tuberculo-
sis drugs has a number of implications.
First, a mechanism is necessary to ensure regular
ARV drug supply, monitoring and drug security to run
in parallel with the existing system for anti-tuberculosis
drugs.
Second, health centres need the capacity to dis-
pense and monitor adherence to ARV drugs. Clinicians
must also be able to recognise drug side effects, the
immune reconstitution syndrome and treatment failure.
Third, adequate human resources are necessary to
perform these additional tasks. Currently only 50%
of available posts in the Malawi MoH are ﬁlled,18 and
90% of health facilities are unable to deliver the es-
sential health package.19 ART cannot be decentralised
without providing the necessary staff to ﬁll existing
gaps and to cover the additional needs for ART. Con-
ditions of service are poor, and staff retention and mo-
tivation are important determining factors that will
also need to be addressed.
Fourth, the decentralisation of ART will have to be
extended to eventually cover all health centres in Thy-
olo district.
Option: Replace NVP in the current 
ART regimen with EFV
Rationale and advantages
When the two drugs are administered concomitantly,
RMP reduces the blood levels of NVP. Increasing the
dose of NVP to compensate for this interaction in-
creases the risk of toxicity, and is thus not recom-
mended.12 ART with Malawi’s current ﬁrst-line regi-
men is thus deferred until after the completion of the
initial phase of anti-tuberculosis treatment. As RMP
has a long half-life, ART is started only 1–2 weeks
after the last dose of RMP. Changing from NVP to
EFV in the ﬁrst-line ART regimen for HIV-positive
TB patients would have the following advantages:
First, ART could be started during rather than 10
weeks after the initiation of anti-tuberculosis treat-
ment. A regimen containing d4T, 3TC and EFV could
potentially be started as early as 2 weeks after starting
anti-tuberculosis treatment. Such a strategy would be
in line with recent WHO recommendations.12 The pa-
tient could then be hospitalised for a much shorter
time. For example, after 2 weeks of initial phase anti-
tuberculosis treatment, the patient could be started
on ART and be discharged, to report back to hospital
after 2 weeks for an assessment. Patients would there-
after return once a month to collect their monthly
supply of drugs, or, if it becomes a reality, receive their
anti-tuberculosis drugs as well as ART at the health
centre level. In any case, such a strategy would provide
the opportunity to adapt the duration of hospitalisa-
tion according to the clinical status and evolution of
the patient.
Second, with EFV there would be no need for a
lead-in dose during the ﬁrst 2 weeks (unlike NVP).
This would make ART initiation more straightfor-
ward for both health personnel and patients.
Third, we have demonstrated that early mortality
in TB patients is a major operational problem in
Thyolo13 and countrywide in Malawi,20 and that deaths
in the ﬁrst 2 months of starting anti-tuberculosis treat-
ment can constitute up to 50% of overall TB mortal-
ity.20 Introducing ART at an earlier stage may result
in a reduction in the current case fatality rate, which
is adversely affecting the credibility of the NTP in the
eyes of health workers, TB patients and the community.
By reducing case fatality rates, ART may also contrib-
ute to improving overall TB treatment outcomes.
Fourth, there is pressure in Malawi, as elsewhere
in sub-Saharan Africa, to replace EH by RH during
the continuation phase of anti-tuberculosis treatment
to reduce rates of recurrent TB.21 RH is also known
to be a more efﬁcacious combination than EH and is
likely to beneﬁt both HIV-positive and HIV-negative
TB patients. As the price of RMP has decreased con-
siderably in the last few years, cost issues are no
longer an impediment to changing to RH.22 Replacing
NVP by EFV in the ﬁrst-line ART regimen for HIV-
positive TB patients would allow an eventual change
from EH to RH in the continuation phase of anti-
tuberculosis treatment without adversely affecting
the feasibility of ART for HIV-positive TB patients.
An ART regimen containing EFV would also allow
standardisation of ART in all anti-tuberculosis regi-
mens, which is currently not the case with ART for
TB meningitis and recurrent TB (Table 1). A possible
scheme for combined anti-tuberculosis treatment and
an EFV-based ART regimen for HIV-positive TB
patients in Thyolo is shown in Table 2.
Operational considerations
Replacing NVP by EFV would have a number of op-
erational implications:
First, unlike the combination of d4T/3TC/NVP,
the combination of d4T, 3TC and EFV is not yet
available as an FDC. The immediate solution would
be to use combined d4T and 3TC, which exists as an
FDC, and give EFV separately. However, this pill bur-
den will be unavoidably higher, making drug admin-
istration more difﬁcult, and in turn possibly adversely
inﬂuencing patient adherence. Furthermore, EFV is
much more expensive than NVP and the overall
cost of such a regimen would be higher. Advocacy for244 The International Journal of Tuberculosis and Lung Disease
making an EFV-containing FDC available at lower cost
is urgently required. An intermediary option could be
to substitute NVP for EFV after the completion of
RMP-based TB treatment. This would allow available
FDC combinations, which include NVP, to be used
after anti-tuberculosis treatment. As both NVP and
EFV belong to the same family of non-nucleoside re-
verse transcriptase inhibitors and are used in ﬁrst-line
regimens, such a strategy should not create the addi-
tional risk of resistance development or compromise
the choice of second-line regimens.
Second, as RMP reduces the therapeutic drug lev-
els of EFV, it is recommended that, in individuals re-
ceiving RMP as well as EFV, the dose of EFV be raised
from 600 mg to 800 mg daily.3 An eventual FDC
combination for HIV-positive TB patients will have
to take this into consideration. The effect of a 30%
increase in standard daily dose of EFV on side effects
in often weak, ill HIV-positive TB patients, who re-
ceive multiple anti-tuberculosis drugs at the same
time, will also have to be evaluated closely.
Third, as EFV is known to be teratogenic, women
of childbearing age would need to be offered effec-
tive, long-term contraception. Most TB patients in
our setting believe that they cannot have sex during
anti-tuberculosis treatment and actually abstain.23
Although this is likely to reduce the overall risk of
pregnancy during anti-tuberculosis treatment, all fe-
male TB patients would need to be offered contracep-
tion. For those women who wish to become pregnant,
the possibility of changing from EFV to NVP at the
end of anti-tuberculosis treatment would have to be
considered. This aspect of care would have to be inte-
grated into the counselling process, and TB pro-
grammes would have to ensure good links with fam-
ily planning services. Effective contraceptive methods
would have to be made available at the ART-TB clin-
ics and staff trained in their use. Long-acting contra-
ceptive preparations such as depo-provera would be
ideal in these circumstances. Although this prepara-
tion is known to provide a higher blood hormone
level than oral contraception, little is known about
how EFV would affect its overall contraceptive efﬁ-
cacy.12 In the absence of such evidence, it would be
wise to recommend additional barrier contraception.
Making male and female condoms available would
also have the additional advantage of ensuring the
prevention of secondary HIV transmission to partners.
Fourth, EFZ cannot be used in children aged <3
years. Although not of major concern, of a total of
23000 annually registered TB cases in Malawi in
1998, up to 1000 patients were aged <3 years.24
Option: Integrate TB and ARV care into 
one clinic at hospital level
Rationale and advantages
TB and ARV treatment currently follow separate cir-
cuits at the hospital level (Figure 2). TB treatment is
administered at the TB ofﬁce and ART in a separate
HIV-ART clinic. For HIV-positive TB patients, it should
be possible to integrate TB treatment and ART into
one clinic (the HIV-ART clinic). This is likely to have
a number of advantages. The services would be more
patient-friendly, as both services would be offered at
the same site, thus avoiding multiple visits by patients
Table 2 Possible scheme for combined anti-tuberculosis treatment and efavirenz-based ART treatment 
for HIV-positive TB patients in Thyolo
Timing* Hospitalisation TB treatment
Sputum
smear†
IEC and
access
to VCT
ART
treatment
ART
consultation
ART counselling and 
drug supply
Day 1 Start of
hospitalisation
Start of initial phase 
(2 months)
X
Day 2–7 X Medical 
screening
Group counselling
Week 2 End of
hospitalisation
Start ART X Individual counselling
Week 4 Ambulatory 
continuation of 
initial phase
X Individual counselling 
and ambulatory 
continuation of ART
Week 8 Start of continuation 
phase (6 months)
XX X
Week 12 X X X
Week 16 X X
Week 20 X X X
Week 24 X X X
Week 28 X X X
Week 32 End of TB treatment X X
Week 40 Continue 
ART
X
*Scheduled visits occur at the end of the speciﬁc week.
†For smear-positive TB cases.
ART 5 antiretroviral treatment; HIV 5 human immunodeﬁciency virus; TB 5 tuberculosis; IEC 5 information, education, communication; VCT 5 voluntary coun-
selling and HIV testing; X 5 scheduled visits.Getting more TB patients on antiretroviral treatment 245
to different sites. This more ‘holistic’ approach may
inﬂuence the patients’ perception of the link between
the two diseases, which in turn may positively inﬂuence
ART-seeking behaviour in TB patients. If ART were de-
centralised to the health centre level, it is likely that
both anti-tuberculosis treatment and ART would be
managed by one clinician. It thus seems logical to try
to ensure a similar approach at the hospital level.
Operational considerations
Such a move would imply good collaboration be-
tween the TB ofﬁce and the HIV-ART clinic. Patient
cards and anti-tuberculosis drugs for HIV-positive TB
patients would need to be transferred at the end of the
hospitalisation period to the HIV-ART clinic, and
treatment for both conditions would have to be ad-
ministered by the same clinician. Monitoring and co-
hort reporting of outcomes for each quarter, which is
currently the responsibility of the district TB ofﬁcer,
would have to be done in close collaboration with the
HIV-ART clinic staff. With the current high HIV
prevalence rates in TB patients, it is possible that a
substantial proportion of TB patients would accept
ART and be managed at the HIV-ART clinic. Hospi-
tal management teams might consider moving one of
their TB ofﬁcers to the ART clinic on a full-time basis
to assist with drug dispensing, monitoring, recording
and reporting.
CONCLUSION
The WHO has set a target of putting over 3 million
people on ART by 2005. It is likely that a substantial
proportion of these will be HIV-positive individuals
with TB who pass through the health system. Less than
5% of all individuals who require ART in sub-Saharan
Africa currently have access to these drugs, and few
programmes at district level offer ART to HIV-
positive individuals with active TB. In Thyolo District
Hospital, despite efforts to initiate ART for HIV-positive
TB patients, we have ended up with a relatively low
uptake. A hospital-based ART programme may sim-
ply not be accessible for a great proportion of patients
who are also receiving anti-tuberculosis treatment.
In Thyolo, there are therefore unrecognised ten-
sions between decentralised TB treatment and the
current centralised ART delivery. Resolving this ten-
sion in different settings will need careful consideration
before the correct operational strategy can be decided.
The option of hospitalising TB patients for 12 weeks
with d4T/3TC/NVP would be a retrograde step for
NTPs that have worked hard towards decentralisa-
tion over the past 5–7 years. Replacing NVP by EFV
in the ﬁrst-line ART regimen, with the option of start-
ing patients after the ﬁrst 2 weeks of initial phase
anti-tuberculosis treatment, seems a good option, as
this would limit the period of initial hospitalisation
for HIV-positive TB patients. The availability of an
FDC that includes EFV would thus be vital to reduce
the overall pill burden. Replacing NVP by EFV would
also seem a rational step to allow standardisation of
the ﬁrst-line ART regimen across all current anti-
tuberculosis regimens. In Thyolo, where the majority
of TB patients are malnourished13 and early TB mor-
tality is extremely high,20 an initial period of hospital-
isation in those who require it should be considered,
as it would seem a logical step to ensure appropriate
management of opportunistic infections, nutritional
rehabilitation and the careful introduction of ART.
The combination of an initial period of hospitalisa-
tion for very ill TB patients along with early initiation
of ART may positively inﬂuence the overall survival
of HIV-positive TB patients in our setting.
Limiting ART delivery to hospitals will challenge
WHO targets for 2005, and there is an urgent need to
ﬁnd solutions that will enable districts such as Thyolo
to decentralise ART along with TB treatment. The need
to decentralise ART also applies to all HIV-positive in-
dividuals. The challenges of decentralisation to dilap-
idated health centres with limited staff, who are gen-
erally poorly qualiﬁed and demotivated, will have to
be addressed. The way forward is one in which TB
and HIV programmes will need to entertain the phi-
losophy of ‘learning by doing’.
We have been late in the ‘doing’, and many thou-
sands of HIV-infected patients in Malawi, as in other
countries in sub-Saharan Africa, have died of AIDS
due to the lack of ART. We must now rapidly face the
uphill task of trying to get more people on ART. The
debate around ‘ways forward’ in getting more HIV-
positive TB patients who pass through the health sys-
tem on ART is part of the struggle.
ART cannot be given in isolation, and it needs to be
placed within a suitable framework of service delivery.25
Making existing decentralised services suitable for
ART delivery means that they will have to be adapted
and improved quickly. The availability of ﬁnancial and
human resources will be a crucial prerequisite for over-
coming the deﬁciencies that are currently a serious ob-
stacle to rapid ART decentralisation. These resources
must be made available. Otherwise, for HIV-positive
people who need ART in districts such as Thyolo, the
WHO targets for 2005 will remain a myth, and many
HIV-positive TB patients will continue to die.
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RÉSUMÉ
L’OMS s’est fixé comme objectif de traiter 3 millions de
personnes au moyen du traitement antirétroviral (ART)
d’ici 2005. En Afrique subsaharienne, les patients tuber-
culeux (TB) séropositifs pour le VIH pourraient contribuer
à cet objectif de manière significative. L’ART (stavudine/
lamivudine/nevirapine) a été mis en route dans le dis-
trict de Thyolo au Malawi en avril 2003, où tous les pa-
tients TB séropositifs ont été considérés comme éligibles
et se sont vus offrir l’ART. Malgré ceci, 44 seulement des
352 patients TB (13%) ont été effectivement mis sous
ART à la fin novembre 2003. Actuellement, la plupart
des patients TB quittent l’hôpital après 2 semaines pour
achever dans la collectivité la phase initiale de leur trai-
tement antituberculeux (basé sur la rifampicine) et l’ART
est offert aux patients TB séropositifs après qu’ils aient
commencé la phase de continuation du traitement (iso-
niazide/éthambutol). L’ART n’est offert qu’à l’hôpital,
alors que la majorité des patients TB prennent la phase
de continuation de leur traitement antituberculeux dans
les centres de santé. Pour cette raison, les patients TB séro-
positifs rencontrent des difficultés pour accéder à l’ART.
Dans cet article, nous discutons une série d’options de
façon à augmenter la prise en charge de l’ART chez les
patients TB séropositifs pour le VIH. Les options princi-
pales sont 1) l’hospitalisation des patients TB séroposi-
tifs avec en vue le démarrage à l’hôpital de l’ART dans
la phase de continuation ; 2) la décentralisation de
l’administration de l’ART de sorte que celui-ci puisse
être administré dans les centres de santé ; 3) le remplace-
ment de la nevirapine par l’efavirenz, ce qui permettrait
de commencer l’ART plus tôt dans la phase initiale du
traitement antituberculeux. La décentralisation de l’ART
depuis les hôpitaux vers les centres de santé améliorerait
considérablement son accessibilité.Getting more TB patients on antiretroviral treatment 247
RESUMEN
La OMS fijó como objetivo para 2005 tratar 3 millones
de personas con tratamiento antirretrovírico (ART). En
África subsahariana, los pacientes con tuberculosis (TB)
y serología positiva para el VIH podrían representar una
proporción considerable de este objetivo. El ART (esta-
vudina, lamivudina y nevirapina) se aplicó por primera
vez en abril de 2003 en el distrito de Thyolo en Malawi ;
se consideró que todos los pacientes seropositivos con
TB eran idóneos y se les propuso el ART. Sin embargo,
a fines de noviembre de 2003 sólo 44 (13%) de los 352
pacientes con TB habían comenzado el ART. En la ac-
tualidad, la mayoría de los pacientes con TB vuelven a la
comunidad después de 2 semanas de hospitalización y
deben completar a domicilio la fase inicial del trata-
miento anti-tuberculosis (con rifampicina) ; además, el
ART se ofrece a los pacientes seropositivos con TB des-
pués del comienzo de la fase de continuación del trata-
miento anti-tuberculosis (isoniacida y etambutol) y ex-
clusivamente en medio hospitalario. Dado que durante
la fase de continuación la mayoría de los pacientes recibe
el tratamiento anti-tuberculosis en los centros de salud,
el acceso al ART es difícil para los pacientes seropositi-
vos con TB.
En este artículo se discuten una serie de opciones para
incrementar la administración del ART a los pacientes
seropositivos con TB. Las principales opciones son : 1)
hospitalizar los pacientes con TB y seropositivos con el
propósito de comenzar el ART, durante la fase de conti-
nuación en medio hospitalario ; 2) descentralizar el su-
ministro del ART, para poder administrarlo en los cen-
tros de salud ; 3) reemplazar la nevirapina por efavirenz,
de manera que el ART pueda comenzarse más tem-
prano, en la fase inicial del tratamiento anti-tuberculo-
sis. La descentralización del ART de los hospitales hacia
los centros de salud mejoraría significativamente la acce-
sibilidad del ART.